Molecular mechanisms involved in the inhibition of tumor cells proliferation exposed to elevated concentrations of the epidermal growth factor

Isabel A Guillén, Jorge Berlanga, Hanlet Camacho, Maria E Fernández-de-Cossio, Lincidio Pérez, Lidia I Novoa, Daniel O Palenzuela, Tamara Díaz, Gerardo E Guillén, Luis Herrera, Karelia Cosme, Laritza Gorovaya, Osmani Mendoza, Julio R Fernández, Julio A Ancizar, José Suárez, Ángela D Tuero, Maria E Ochagavia, Juan Roca, Jorge Gavilondo, Diana García del Barco, Jorge Martín

Centro de Ingeniería Genética y Biotecnología, CIGB
Ave. 31 e/ 158 y 190, Cubanacan, Playa, CP 11600, La Habana, Cuba

ABSTRACT

The EGF promotes inhibition of cell proliferation in vitro and in vivo models depending on its concentration, application schema and the type of tumor cells on which it acts. Our research hypothesis was based on the fact that the EGF varies the expression of genes involved in a negative regulation of tumor cell lines proliferation carrying high levels of its receptor (EGFR). Our objectives were, to obtain information about the effect of EGF on tumor cell proliferation in vitro and in vivo models and, know the gene expression patterns of a group of genes involved in cancer signaling pathways and EGFR. The results showed that EGF at nanomolar concentrations inhibits the tumor cells proliferation bearing high levels of EGFR and, promotes the survival of treated animals, establishing a direct relationship between the inhibition of cell proliferation, high concentrations of EGF and, high amount of EGFR in the cells. The differential gene expression profile showed a variation in a group of genes which exert a powerful control over the cell cycle progression, gene transcription and apoptosis. It was concluded that the inhibition of tumor cell proliferation by the action of EGF is due to activation of molecular mechanisms controlling cell cycle progression. This work won the Annual Award of the Cuban Academy of Sciences in 2012.

Keywords: epidermal growth factor, cancer, gene expression, animal model

Introduction

Epidermal growth factor (EGF) is a 6 kDa polypeptide that binds to its receptor (EGFR), a tyrosine kinase that activates transduction signals promoting the transcription of genes involved in growth and proliferation of different cell types. The exogenous administration of supraphysiological concentrations of EGF triggers reparative and cytoprotective effects which lead to cell survival and the repair of internal and external organs [1]. EGF and its receptor have also been implicated in human malignancies because of the interconnection of wound healing and the development of tumors favored by the dynamic interaction of a variety of cell types to promote cell proliferation and survival. Recent evidence from animal models suggests that EGF does not initiate cell transformation, and its role in carcinogenesis is only as a promoting agent, acting as an epigenetic factor when cells are prone to malignancy [2]. It has been observed that depending on EGF concentrations, the application schema and type of cells on which it acts can inhibit or promote cell growth, showing a biphasic action on tumor cell lines of epithelial origin. For example, picomolar concen-


Corresponding author

© Corresponding author
trations (3-100 pM) of EGF promote tumor cell proliferation, and nanomolar concentrations (0.1-10 nM) cause its inhibition [3-7].

This paradox suggests that the high availability of EGFR in cells and high EGF concentrations produces a negative cooperation between the EGFR dimerized receptors, supporting the formation of a low affinity receptor for the ligand, and activating signaling pathways that have a negative effect on cell proliferation [8].

Taking all these into account, we set out to find genes involved in the negative regulation of the proliferation of tumor cell lines carrying high concentrations of EGFR by exposing them to nanomolar concentrations of the ligand (EGF). For this purpose, we developed the following objectives: to obtain information about the effect of EGF on the proliferation and development of tumor cells in models in vitro and in vivo; and, to know the gene expression patterns of a selected group of genes related to the signaling cancer pathways and EGFR.

Materials and methods

We used six cancer cell lines (K562, MCF-7, U1906, LS-174T, H125 and A431) with different concentrations of EGFR. These cell lines were exposed for 72 h to the ligand effect (EGF). An animal model was obtained in nude mice xenografts with the cell line A431 over-expressing the levels of EGFR. The animals were treated subcutaneously in the dorsal region, near to the tumor with 1 µg/kg of EGF. The real time polymerase chain reaction (RT-PCR) technique was used to explore the differential expression of 44 genes involved in EGF signaling pathway and cancer in cells treated with EGF and controls, in in vitro and in vivo models. The quantitative RT-PCR data analysis was performed by RT-Cycler CapitalBio series analysis software, version 2.001 (CapitalBio Co., Ltd., Beijing, China). Relative quantification of gene expression was performed using the software REST 2009 v2.0.13 (Qiagen GmbH, Germany). The LinReg software (version 11.3, 2009, Amsterdam, Netherlands) was used to estimate the efficiency of PCR and the geNorm software was used for the selection of more stable reference genes [9].

Results and discussion

EGF at concentrations of 2.2, 33 and 165 nM does not favor the proliferation of tumor cells. Interestingly was observed that EGF inhibited the proliferation of tumor cells over-expressing the growth factor receptor (EGFR), such as H125 (lung adenocarcinoma carcinoma cell line) and A431 (epidermoid carcinoma of the vulva cell line). According to these results, there is a direct relationship between the inhibition of cell proliferation, the exposition of cancer cells to high concentrations of exogenous EGF and, the high amount of endogenous EGFR in cells (Figure 1).

We observed an inhibition of tumor growth in the in vivo model of nude mice xenografted with the A431 cell line and treated with EGF for 5 weeks (Figure 2), there was obtained a decrease in the mitotic index of tumor cells, which is a critical parameter in the prevention and control of cancer [10]. Since EGF may provide protective effects against the aggressiveness and invasiveness of certain types of tumors, it was observed in the in vivo study a significant increase in survival of the animals inoculated with 3 × 10^6 A431 cells and treated with EGF in comparison with the untreated animals [10]. The EGF favored the survival of animals, perhaps by providing protective properties against tumor aggressiveness and invasiveness. As proposed by Amagase et al. in 1990, EGF plays an important role in preventing metastasis of certain malignancies, thus prolonging the survival time of xenotransplanted athymic animals [11].

The differential gene expression analysis in in vivo and in vitro studies revealed the over-expression of genes that directly and potently regulate cell cycle progression and apoptosis. This was detected by analyzing the differential gene expression profile in the tumors and cell lines.

For the cell line H125, 21 genes varied significantly their expression, with 27 in A431. However, in the U1906 cell line, only 3 genes varied its expression. This shows a correspondence between the magnitude of the gene expression variability and the observed phenotype.

In the A431 and H125 cell lines, similar genes were over-expressed and inhibited; among them having a fold change above 2 (FC ≥ 2): ITG2A, CDKN1A/ P21, CCNE1, TIMP1, RASA1, ITGB1, IRF1, and IGFBP3. Most of them are part of the EGF/EGFR signaling cascade, which regulates cell cycle progression and apoptosis.

A scheme of the identified molecular interactions showing the most relevant genes in gene expression analysis is shown in Figure 3. As can be observed there were genes with FC > 1.5, with statistically significant differences between treated and control cells of A431 and H125 tumor cell lines.

Also, a specific group of genes for each cell line were involved in the process of cell proliferation inhibition. In the cell line A431, the activation of the transcription factor STAT1 induces the expression of genes involved in apoptosis and in the inhibition of the TP53 gene, which carries a gain-of-function mutation favoring cell tumorigenicity. Furthermore, in the H125 cell line was observed the over-expression of pro-apoptotic genes, such as caspases 8 and 9.

In general, the molecular mechanisms involved in the inhibition of tumor cell proliferation in both scenarios (in vitro and in vivo), were directed by the variation in the expression of genes that control cell cycle progression, such as the cyclin-dependent kinase inhibitor CDKN1A, and cyclin-dependent kinase 4 (Cdk4). The way in which these genes changed its expression may justify the phenotypic effect mediated by the action of EGF in tumor cells.

As already mentioned, the gene expression for the tumor suppressor gene TP53 varied similarly in the A431 in studies in vivo and in vitro. The TP53 protein controls the cell cycle progression to repair the damage in the genome. In the A431 cell line, TP53 gene has a point mutation p.Arg273His, which is a change at the arginine residue 273 to histidine. This is a gain-of-function type I mutation (type I missense mutation), which affects the binding sites of the p53 protein to the DNA. Therefore, the G1/S checkpoint in the cell cycle does not function properly to repair...
the genetic damage [12]. This causes a genomic instability and malignant progression of cells. Among the phenotypic effects of the mutated TP53 on the cells are: increased cell proliferation, increased growth density and induction of antiapoptotic activity [13].

The inhibition of the mutated TP53 gene expression in the A431 cell line treated with EGF may be associated to a decrease in tumorigenicity of the mutated protein. A decrease in the levels of this protein may allow the cell to recover somewhat the regulation of cell cycle progression at the G1-S transition, by decreasing Cdk4 levels. We observed a possible link between the effect of EGF and the inhibition of two important cell cycle regulators, the TP53 and Cdk4, and its implications in the inhibition of cell cycle progression from G1 to S phase, thereby, decreasing tumor growth. These results suggest that EGF promotes similar mechanisms in both biological scenarios (in vivo and in vitro) in the A431 cell line, resulting in an inhibition of cell proliferation.

Figure 1. In vitro analysis of cellular proliferation in cells with intermediate (LS-174T) or high (A431 and HT125) percentage of epidermal growth factor receptor (EGFR). Bars represent the mean (± SD) of tumor cell counts per milliliters. Cells were treated with different concentrations of recombinant human EGF and control, and were compared using Student’s t-test applied to independent samples to determine the existence of statistically significant differences between treatments. The samples were also compared to a control of untreated cells. * Denotes the statistical significance of the differences between the treatments (p < 0.05).
Caspase 9 is another gene in the regulatory cascade of EGF on tumor cells bearing high levels of EGFR. This gene is a member of the aspartic acid protease-cysteine family. The sequential activation of caspases plays a central role in cellular apoptosis, so that the action of EGF on restoring antitumor cell biological pathways may also be taking place through activation of the caspase pathway. The activation of caspases 8 and 9 were also detected in the H125 cell line treated with EGF. This is another regulatory pathway activated in cancer models in vivo and in vitro treated with the EGF. The in vivo scenario promotes transient recovery of the cellular tumor suppressor ability, by reducing gene expression levels of Cdk4 and TP53, and increasing caspase 9 levels. The in vitro models revealed a group of genes that varies in a similar fashion in the A431 and H125 cell lines, which inhibited the EGF-mediated proliferation.

All these genes are involved in the signaling cascade of EGF/EGFR and cancer. It is relevant the activation by EGF of the expression of integrins like ITGA2 and ITGB1 (Figure 3), which in turn activates the signaling cascade through EGFR. These signals may induce the expression of integrins, a family of transmembrane glycoprotein receptors that mediate cell-cell and cell-matrix interactions, playing a fundamental role in cellular events such as proliferation, differentiation and apoptosis. It is also known that the over-expression of the beta1 integrin inhibits cell proliferation through the activation of the cyclin dependent kinase inhibitor p21. Integrin over-expression can reduce cell adhesion and can inactivate the phosphoinositide 3 kinase (PI3K) [14].

The protein encoded by the p21 gene is the cyclin dependent kinase inhibitor 1A (CDKN1A), which regulates the cell cycle S phase progression. The P21 expression is regulated by the tumor suppressor gene TP53. It has also shown to be regulated by other genes such as the integrins, through its effect on the PI3K / AKT1 pathway of the EGFR signaling cascade.

The STAT1 transcription factor is another interesting gene, which, as has been reported by other groups, is activated in the A431 cell line [15]. Its activation is associated with a decrease in cell proliferation and increased apoptosis, and is further required to inhibit the proto-oncogene MYC, which directs cell proliferation through the over-expression of cyclins and gene expression inhibition of p21. In the A431 cell line, the expression of MYC was inhibited, and, therefore, it must favor the cell proliferation inhibition observed in these cells.

On the other hand, the TIMP1 gene is a metalloprotease inhibitor that was over-expressed in A431 and H125 cell lines. This factor forms complexes with matrix metalloproteinases (MMP) and irreversibly inactivates collagenase. MMPs belong to the extracellular matrix (ECM) which activates the integrins. It is known that there must be a balance between the levels of proteases and their inhibitors to form a correct ECM, which is a component of the granulation tissue, a key component of wound healing and tissue regeneration. Moreover, one of the key events in malignant tumor development is the degradation of the ECM, which at the time is essential for angiogenesis and the formation of blood vessels from preexisting blood networks.

Another interesting gene was RASA1, showing increased expression in both, the A431 and H125 cell lines. The RASA1 protein is a negative regulator of the RAS/MAPK signaling pathway, which transmits signals from outside the cell into the nucleus. The signaling pathway through RAS/MAPK directs important functions such as cell growth and division. When RASA1 is mutated, there is a path of deregulation through RAS/MAPK pathway, which promotes uncontrolled proliferation and cancer development.
In this scenario, not everything is an antiprolifera-
tive and pro-apoptotic stage, as has been arising from
the explanation for the inhibition seen in cell prolif-
eration and tumor growth, promoted by genes such as:
TIMP1, p21, Cdk4, ITGA2, ITGB, TP53, MYC,
RASA1 and caspases 8 and 9. There was also a group
of genes that varied their expression, which partici-
pare in cell proliferation promotion. This is the case
of the over-expression of the CCNE1 gene, a member
of the cyclins family, which positively regulates the
G1/S transition.

In a complex scenario such as the EGF/EGFR sig-
naling cascade, it is significant that the cell promotes
activation of powerful regulatory mechanisms. Those
mechanisms maintain the control over the oncogenic
effects that can trigger and support uncontrolled cell
proliferation and cancer development.

Recent reports suggest that EGF induces more
changes in cell proliferation and death in A431 cancer
cells than the anticancer drugs cetuximab or gefitinib
[16]. Cell arrest and death events produced by EGF
appear to remain for periods longer than those caused
by some conventional antitumor drugs. This is impor-
tant to continue unraveling the complex molecular
mechanisms of EGF in cell proliferation inhibition in
cancer cells.

**Conclusions**

This is the first study in Cuba exploring the mecha-
nism of action of EGF using the RT-PCR technique
to quantify the differential gene expression profile of
44 genes involved in cancer pathways and the EGF/
EGFR signaling. It is also the first time that the inhibi-
tory effect of EGF on cell proliferation is related to the
gene expression levels of the mutant TP53p.Arg273His
and the inhibition of cell proliferation in an *in vivo* and
*in vitro* model using the vulva cancer cell line A431.

The antiproliferative effects of EGF were medi-
ated by changes detected in the expression of genes
which regulate cell cycle progression, apoptosis and
transcription. They included the effect of the gene de-
dependent kinases inhibitor (CDKN1A) which regulates
cell cycle progression, and the caspase 8 and 9, and
the transcription factor STAT1 genes.

There is a functional convergence between EGFR
expression levels in cells and the signaling through
integrins, thus favoring the over-expression of the cell
cycle inhibitor gene CDKN1A/P21. It was also ob-
served that EGF at a 2.2 nM concentration signifi-
cantly promotes survival of treated animals when placed
subcutaneously near to the tumor generated in nude
mice xenografted with the A431 cell line.

16. Song JY, Lee SH, Hong JP, Chang SE, Choe H, Choi J. Epidermal growth factor
competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing